Spots Global Cancer Trial Database for conditioning regimen
Every month we try and update this database with for conditioning regimen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | NCT00189488 | Graft Versus Ho... Hematologic Mal... | Palifermin Placebo Conditioning Re... Allogeneic stem... Methotrexate | 18 Years - | Swedish Orphan Biovitrum | |
| Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine | NCT06060782 | Burkitt Lymphom... Lymphoblastic L... Acute Lymphobla... | Thiotepa, cyclo... | 18 Years - 65 Years | Fifth Affiliated Hospital, Sun Yat-Sen University | |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | NCT04395092 | Acute Myeloid L... Myelodysplastic... | K-NK002 Conditioning Re... HaploBMT | 18 Years - 65 Years | Kiadis Pharma | |
| Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) | NCT01379209 | Graft Versus Ho... | RGI-2001 Calcineurin Inh... Allogeneic Hema... Conditioning Re... Allogeneic Bone... Methotrexate Mofetil Mycophe... sirolimus | 18 Years - | Regimmune Corporation | |
| The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma | NCT01235793 | B-Cell Lymphoma... | Temozolomide | 18 Years - 75 Years | Cedars-Sinai Medical Center | |
| Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission | NCT02605460 | Acute Myeloid L... Acute Lymphoid ... | Busulfan Cyclophosphamid... CXCR4 Antagonis... Hematopoietic S... | 18 Years - 60 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | |
| Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia | NCT00797758 | Acute Myeloid L... | Cord blood tran... | 4 Years - 65 Years | Assistance Publique - Hôpitaux de Paris | |
| Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia | NCT00797758 | Acute Myeloid L... | Cord blood tran... | 4 Years - 65 Years | Assistance Publique - Hôpitaux de Paris | |
| Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML | NCT06385808 | Relapse Leukemi... Refractory Acut... Conditioning Hematopoietic S... | MTBF regimen | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | NCT04395092 | Acute Myeloid L... Myelodysplastic... | K-NK002 Conditioning Re... HaploBMT | 18 Years - 65 Years | Kiadis Pharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
